Literature DB >> 12734865

Use of transpelvic rectus abdominis musculocutaneous flap for anal cancer salvage surgery.

T M Tei1, T Stolzenburg, S Buntzen, S Laurberg, H Kjeldsen.   

Abstract

BACKGROUND: Perineal wounds following abdominoperineal resection (APR), for persistent or locally recurrent anal cancer, are associated with poor healing secondary to irradiation therapy. The results of APR combined with a vertical rectus abdominis musculocutaneous (VRAM) flap transposed transpelvically to cover the perineal defect are presented.
METHODS: Between 1994 and 2000, 105 patients were diagnosed and treated for anal cancer. Twenty-two (21 per cent) underwent a salvage operation owing to persistent or locally recurrent disease. In eight patients, before 1996, the perineum was closed primarily with serious wound complications in five. In the final 14 patients, primary perineal reconstruction with a VRAM flap was performed.
RESULTS: Median age was 65.5 (range 45-78) years. Median follow-up was 14.5 (range 3-41) months. There were no flap-related complications and primary healing was achieved in all patients. Median hospital stay was 17 (range 14-72) days. There were two major complications related to the laparotomy and abdominal closure.
CONCLUSION: Combining the salvage operation with a VRAM flap facilitates primary healing after surgical treatment for persistent or locally recurrent anal cancer. A single-stage primary reconstructive procedure is feasible, with an acceptable complication rate and high level of patient satisfaction. Copyright 2003 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2003        PMID: 12734865     DOI: 10.1002/bjs.4073

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  22 in total

1.  Reconstruction of the irradiated extended abdominoperineal excision (APE) defect for locally advanced colorectal cancer.

Authors:  Mark A Boccola; Warren Matthew Rozen; Edmund W Ek; Damien Grinsell; Matthew A Croxford
Journal:  J Gastrointest Cancer       Date:  2011-03

2.  Complications of perineal surgery.

Authors:  James W Ogilvie; Rocco Ricciardi
Journal:  Clin Colon Rectal Surg       Date:  2009-02

3.  Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer.

Authors:  Floris T J Ferenschild; Maarten Vermaas; Stefan O Hofer; Cornelis Verhoef; Alexander M M Eggermont; Johannes H W de Wilt
Journal:  World J Surg       Date:  2005-11       Impact factor: 3.352

4.  Predictors of Perineal Wound Complications and Prolonged Time to Perineal Wound Healing After Abdominoperineal Resection.

Authors:  Azah A Althumairi; Joseph K Canner; Susan L Gearhart; Bashar Safar; Justin Sacks; Jonathan E Efron
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

5.  A hundred patients with vertical rectus abdominis myocutaneous (VRAM) flap for pelvic reconstruction after total pelvic exenteration.

Authors:  R E Horch; W Hohenberger; A Eweida; U Kneser; K Weber; A Arkudas; S Merkel; J Göhl; J P Beier
Journal:  Int J Colorectal Dis       Date:  2014-04-22       Impact factor: 2.571

6.  Epidermoid cancer of the anal canal.

Authors:  Shawn P Webb; Chong S Lee
Journal:  Clin Colon Rectal Surg       Date:  2011-09

Review 7.  Prevention and management of nonhealing perineal wounds.

Authors:  Allen Kamrava; Najjia N Mahmoud
Journal:  Clin Colon Rectal Surg       Date:  2013-06

Review 8.  Management of the Perineal Defect after Abdominoperineal Excision.

Authors:  Colin Peirce; Sean Martin
Journal:  Clin Colon Rectal Surg       Date:  2016-06

9.  Perineal wound complications after abdominoperineal resection.

Authors:  Rebecca L Wiatrek; J Scott Thomas; Harry T Papaconstantinou
Journal:  Clin Colon Rectal Surg       Date:  2008-02

10.  Reconstruction of the perineum following anorectal cancer excision.

Authors:  Nicola Petrie; Graham Branagan; Caroline McGuiness; Shaun McGee; Clare Fuller; Helen Chave
Journal:  Int J Colorectal Dis       Date:  2008-08-08       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.